News headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioverativ earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.1182637788403 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s analysis:
- Sanofi in talks with Advent to sell its European generics arm for €1.9bn (cityam.com)
- Peregrine Capital Management Llc Buys Lumentum Holdings Inc, Box Inc, Gates Industrial Corp PLC, Sells Bioverativ … (gurufocus.com)
- Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia (businesswire.com)
- $0.27 EPS Expected for Delta Apparel, Inc. (DLA); Bioverativ (BIVV) Shorts Down By 76.05% (mtastar.com)
- Acadian Asset Management Llc Buys Exxon Mobil Corp, The Home Depot Inc, The Estee Lauder Inc, Sells Alibaba … (gurufocus.com)
Shares of Bioverativ stock remained flat at $$104.98 on Wednesday. Bioverativ has a 52 week low of $48.14 and a 52 week high of $105.01.
A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research note on Monday, January 8th. Raymond James lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Jefferies Group lifted their price objective on Bioverativ to $79.00 and gave the company a “buy” rating in a research note on Thursday, January 18th. Morgan Stanley upgraded Bioverativ from an “underweight” rating to an “equal weight” rating in a research note on Tuesday, January 23rd. Finally, Credit Suisse Group restated a “neutral” rating and issued a $65.00 price target on shares of Bioverativ in a research note on Thursday, January 18th. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $64.70.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2018/04/18/bioverativ-bivv-receives-coverage-optimism-score-of-0-14.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.